Recurrent Melanoma Suspended Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03050060Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTreatment